GLP-1s are transforming the treatment of diabetes and obesity, but could their benefits extend to venous thromboembolism (VTE)? And what should clinicians tell patients with a history of VTE?

Join host Julia Sandrin Gauer and experts Christian Ruff and Rushad Patell as they discuss:

• What current evidence suggests about GLP-1 therapies and VTE risk
• The limitations of existing clinical trial and observational data
• Whether GLP-1 and multi-incretin therapies may have different effects
• What these findings mean for clinical practice, and the questions that remain

Tune in now to this special collaboration between the ISTH Pulse Podcast and Vasculearn Network’s Clot, Clot, Who’s There?, for this timely conversation!